Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Publikováno v:
Drug Design, Development and Therapy
Yueyue Liu, Qian Zhang, Chao Lu, Wei Hu Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, 230601, People’s Republic of ChinaCorrespondence: Chao Lu; Wei HuDepartment of Clinical Pharmacology, The Second Ho
Autor:
Alfizah Hanafiah, Mohd Fahami Nur Azlina, Adam Quraisiah, Fazalda Annuar, Sophia Ogechi Ekeuku, Benjamin Ka Seng Thong, Kok-Yong Chin
Publikováno v:
Drug Design, Development and Therapy. 14:5359-5366
Purpose Triple therapy is the standard therapy to eradicate Helicobacter pylori (H.pylori) infection. Chronic use of proton pump inhibitors (PPIs), a component of triple therapy, is associated with osteoporosis. However, the skeletal effects of short
Publikováno v:
Drug Design, Development and Therapy. 14:519-526
Introduction Hesperetin-5,7,3'-O-trimethylether (HTME), a synthetic liposoluble hesperetin, has been reported to be a dual phosphodiesterase (PDE)3/4 inhibitor. We investigated its inhibitory effects on methacholine (MCh)-induced airway hyperresponsi
Publikováno v:
Drug Design, Development and Therapy. 13:3887-3898
Purpose Dexmedetomidine [DEX; (S)-4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole] is a selective α2-adrenergic receptor (α2-AR) agonist that attenuates the liver damage associated with local or systemic inflammation. However, it remains unclear wheth
Publikováno v:
Drug Design, Development and Therapy
Jiaying Lin,* Ningling Wang,* Jialv Huang, Renfei Cai, Yong Fan, Yanping Kuang, Yun Wang Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
Autor:
Baoan Chen, Chunyan Luan
Publikováno v:
Drug Design, Development and Therapy. 13:2899-2909
Alkylators and nucleoside analogs were the main drugs for treatingchronic lymphoblastic leukemia (CLL), which have been replaced by monoclonal antibodies, such as rituximab in the past 10 years for refractory or relapsed CLL. The first-line immunoche
Autor:
Weizhu Qian, Sheng Hou, Qing An, Huaizu Guo, Yirong Zhao, Jing Li, Yajun Guo, Tao Liu, Dapeng Zhang, Hao Wang, Yingxin Zheng
Publikováno v:
Drug Design, Development and Therapy. 13:791-805
Background Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to gu
Autor:
Miglė Paškevičiūtė, Vilma Petrikaitė
Publikováno v:
Drug Design, Development and Therapy
MiglÄ PaškeviÄiÅ«tÄ,1 Vilma PetrikaitÄ1,21Department of Drug Chemistry, Faculty of Pharmacy, Lithuanian University of Health Sciences, Kaunas, Lithuania; 2Department of Biothermodynamics and Drug Design, Vilnius University Institute of
Publikováno v:
Drug Design, Development and Therapy
Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a su